News & Events

News

All categories

Earnings

Press Release

All years

2019

2018

2017

2016

2015

2014

Affimed Announces Closing of Initial Public Offering

September 17, 2014

Affimed Announces Pricing of Initial Public Offering

September 12, 2014

Affimed Secures $29.7M in Private Financing from Current and New Investors

September 2, 2014

Ferdinand Verdonck Elected to Affimed’s Supervisory Board

July 25, 2014

Affimed Files Registration Statement for Proposed Initial Public Offering

June 30, 2014

Affimed Highlights Further Data on AFM13, a Bispecific CD30/CD16A TandAb in Development to Treat Hodgkin Lymphoma, at the 2014 AACR Annual Meeting

April 10, 2014

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Events

All

Scientific

Investors

30Sep

NK2019

September 30 - October 3, 2019 (Luxembourg)

Webcasts
More events

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.